THE PERCAYAI SOFTWARE PLATFORM
DESIGNED TO BE FUNDAMENTALLY DIFFERENT
SIMPLIFIED DATA FABRIC
Automated data assembly instead of manual curation of disparate data sources.
NO MODEL TRAINING REQUIRED
Ontology free; Works out of the box, no additional manual training needed.
TRANSLATABLE
Enable better mouse to human translations by finding conserved contextual biology, a game-changer contrary to simplistic gene to gene comparisons.
WORKS ACROSS ALL DISEASE AREAS
Singular model equally relevant and disease-agnostic, obviates the need to build multiple AI models to address multiple diseases.
FULLY INTEGRATED PLATFORM FOR ALL STAGES OF SCIENTIFIC DISCOVERY
Omics analysis
Enabled by CompBio
Analyze omics and multi-omics datasets to identify contextually similar biology using published biological literature.
Explore the most integral and contextually relevant biology underlying personal or public datasets and the sources driving each insight.
With one tool that works across all disease areas and avoids the limitations and bias of human-curated ontologies, get an interactive 3D visualization of your omics data.
Explore all biology
Enabled by BioExplorer
Auto-curate a 3D, interactive knowledge map that allows you to quickly search and review biology within or outside your area of expertise.
Use concept-level comparisons to identify interactions between targets and processes, diseases, drugs, and more.
Rank and compare
Enabled by the Assertion Engine
With our most advanced feature, make rapid comparison across many datasets with just a few clicks.
-
Identify animal model relevance to human disease states
-
Compare analyses across multiple time points to identify conserved biology
-
Identify mechanisms of action and druggable targets
Rapid comparisons across datasets
Get started with the PercayAI software platform today
See it in action
Testimonials
"With its ease of use and ability to generate novel insights, PercayAI software has become a routine part of our analysis pipeline for multi-omics datasets."
Michael Barratt, PhD
Executive Director, Laboratory of Dr. Jeffrey Gordon
Washington University School of Medicine in St. Louis
TODAY
1 in 10
Drugs that enter clinical trials make it to market across all indications¹
¹Center for Medical Research
>50%
Failure rate in Phase 2 and 3 clinical trials² because targets were not linked to disease³
²Harrison 2016 Nat Rev Drug Discovery
³Morgan et al 2018 Nat Rev Drug Discovery
THE FUTURE WITH PERCAYAI: ENHANCED EFFICACY
2x
What if we could get more qualified drugs into clinical trials?
